Clinical translation is ongoing, with one microbubble formulation targeted to vascular endothelial growth factor receptor 2 (VEGFR2) showing potential for diagnostic imaging in patients with prostate cancer [24] and breast and ovarian lesions [19], both first-in-human studies. This evidence concerns the gene KDR and prostate cancer.